m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02570)
Name
Progesterone
Synonyms
Piaponon; Pregnenedione; Primolut; Progestasert; Progesterol; Progesteronum; Progestin; Progestone; Progestosol; Progestron; Progestronol; Prometrium; Protormone; Pregn-4-ene-3,20-dione; Syngesterone; Syntolutan; Utrogestan; progesterone; Agolutin; Corlutin; Corpus luteum hormone; Crinone; Cyclogest; Flavolutan; Gestone; Gestormone; Glanducorpin; Gynolutone; Hormoflaveine; Hormoluton; Lingusorbs; Luteogan; Luteohormone; Luteol; Luteopur; Luteosan; Luteostab; Luteovis; Lutociclina; Lutocylin; Lutromone; Methylpregnone; 4-Pregnene-3,20-dione; 57-83-0
    Click to Show/Hide
Status
Approved
Structure
Formula
C21H30O2
InChI
1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
InChIKey
RJKFOVLPORLFTN-LEKSSAKUSA-N
PubChem CID
5994
VARIDT Drug ID
DR00281
INTEDE Drug ID
DR1346
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aldo-keto reductase 1C1 (AKR1C1)
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aldo-keto reductase 1C1 (AKR1C1) is a therapeutic target for Progesterone. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Progesterone through regulating the expression of Aldo-keto reductase 1C1 (AKR1C1). [1], [2]
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of Breast cancer resistance protein (ABCG2). [3], [4]
Cytochrome P450 1B1 (CYP1B1)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Progesterone. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of Progesterone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [5], [6]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Cytochrome P450 1B1 (CYP1B1) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of Cytochrome P450 1B1 (CYP1B1). [6], [7]
P-glycoprotein 1 (ABCB1)
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Progesterone. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of Progesterone through regulating the expression of P-glycoprotein 1 (ABCB1). [8], [9]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary P-glycoprotein 1 (ABCB1) is a therapeutic target for Progesterone. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Progesterone through regulating the expression of P-glycoprotein 1 (ABCB1). [3], [9]
References
Ref 1 YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019 Oct 25;10(1):4892. doi: 10.1038/s41467-019-12801-6.
Ref 2 Human 3-alpha hydroxysteroid dehydrogenase type 3 (3Alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20Alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43. doi: 10.1016/j.jsbmb.2014.01.003. Epub 2014 Jan 13.
Ref 3 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 4 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. doi: 10.1074/jbc.M301358200. Epub 2003 Mar 28.
Ref 5 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.
Ref 6 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13. doi: 10.1093/carcin/20.8.1607.
Ref 7 METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation. Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F839-F847. doi: 10.1152/ajprenal.00222.2020. Epub 2020 Sep 21.
Ref 8 Binding of RNA m6A by IGF2BP3 triggers chemoresistance of HCT8 cells via upregulation of ABCB1. Am J Cancer Res. 2021 Apr 15;11(4):1428-1445. eCollection 2021.
Ref 9 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. doi: 10.1023/a:1013358126640.